TOKYO -- Fujifilm Holdings will supply an active ingredient for late-stage testing of a coronavirus vaccine being developed by U.S.-based Novavax, the Japanese company said Friday.
Subsidiary Fujifilm Diosynth Biotechnologies is already producing the bulk drug substance for the vaccine candidate at a plant in the U.S. state of North Carolina.
